Fibrocytes: A Novel Stromal Cells to Regulate Resistance to Anti-Angiogenic Therapy and Cancer Progression

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2017 Dec 30

PMID 29286323

Citations 10

Authors

Hisatsugu Goto

Yasuhiko Nishioka

Affiliations

Soon will be listed here.

Abstract

An adequate blood supply is essential for cancer cells to survive and grow; thus, the concept of inhibiting tumor angiogenesis has been applied to cancer therapy, and several drugs are already in clinical use. It has been shown that treatment with those anti-angiogenic drugs improved the response rate and prolonged the survival of patients with various types of cancer; however, it is also true that the effect was mostly limited. Currently, the disappointing clinical results are explained by the existence of intrinsic or acquired resistance to the therapy mediated by both tumor cells and stromal cells. This article reviews the mechanisms of resistance mediated by stromal cells such as endothelial cells, pericytes, fibroblasts and myeloid cells, with an emphasis on fibrocytes, which were recently identified as the cell type responsible for regulating acquired resistance to anti-angiogenic therapy. In addition, the other emerging role of fibrocytes as mediator-producing cells in tumor progression is discussed.

Citing Articles

Precision Medicine for Metastatic Colorectal Cancer: Where Do We Stand?.

Underwood P, Pawlik T Cancers (Basel). 2024; 16(22).

PMID: 39594824 PMC: 11593240. DOI: 10.3390/cancers16223870.

Lung cancer organoids: models for preclinical research and precision medicine.

Liu Y, Zhou Y, Chen P Front Oncol. 2023; 13:1293441.

PMID: 37941550 PMC: 10628480. DOI: 10.3389/fonc.2023.1293441.

Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments.

Tang Y, Li D, Duan J, Sheng L, Wang X World J Gastroenterol. 2023; 29(6):926-948.

PMID: 36844139 PMC: 9950860. DOI: 10.3748/wjg.v29.i6.926.

Analysis of the chemotactic factors for tumor-infiltrating fibrocytes and their prognostic significances in lung cancer.

Tobiume M, Mitsuhashi A, Saijo A, Ogino H, Afroj T, Ogawa H Oncol Lett. 2022; 24(5):417.

PMID: 36245829 PMC: 9555093. DOI: 10.3892/ol.2022.13537.

Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.

Afroj T, Mitsuhashi A, Ogino H, Saijo A, Otsuka K, Yoneda H J Immunol. 2021; 206(6):1204-1214.

PMID: 33504617 PMC: 7939041. DOI: 10.4049/jimmunol.2000909.

References

Al-Abd A, Alamoudi A, Abdel-Naim A, Neamatallah T, Ashour O . Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review. J Adv Res. 2017; 8(6):591-605. PMC: 5544473. DOI: 10.1016/j.jare.2017.06.006. View

Gomperts B, Strieter R . Fibrocytes in lung disease. J Leukoc Biol. 2007; 82(3):449-56. DOI: 10.1189/jlb.0906587. View

Vasudev N, Reynolds A . Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014; 17(3):471-94. PMC: 4061466. DOI: 10.1007/s10456-014-9420-y. View

Valkovic T, Dobrila F, Melato M, Sasso F, Rizzardi C, Jonjic N . Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma. Virchows Arch. 2002; 440(6):583-8. DOI: 10.1007/s004280100458. View

Laurent J, Touvrey C, Botta F, Kuonen F, Ruegg C . Emerging paradigms and questions on pro-angiogenic bone marrow-derived myelomonocytic cells. Int J Dev Biol. 2011; 55(4-5):527-34. DOI: 10.1387/ijdb.103228jl. View

Ribatti D . Tumor refractoriness to anti-VEGF therapy. Oncotarget. 2016; 7(29):46668-46677. PMC: 5216828. DOI: 10.18632/oncotarget.8694. View

Ceradini D, Kulkarni A, Callaghan M, Tepper O, Bastidas N, Kleinman M . Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004; 10(8):858-64. DOI: 10.1038/nm1075. View

Folkman J . Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg. 1972; 175(3):409-16. PMC: 1355186. DOI: 10.1097/00000658-197203000-00014. View

Sims D . The pericyte--a review. Tissue Cell. 1986; 18(2):153-74. DOI: 10.1016/0040-8166(86)90026-1. View

10.

Vences-Catalan F, Rajapaksa R, Srivastava M, Marabelle A, Kuo C, Levy R . Tetraspanin CD81 promotes tumor growth and metastasis by modulating the functions of T regulatory and myeloid-derived suppressor cells. Cancer Res. 2015; 75(21):4517-26. DOI: 10.1158/0008-5472.CAN-15-1021. View

11.

Gotink K, Broxterman H, Labots M, de Haas R, Dekker H, Honeywell R . Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res. 2011; 17(23):7337-46. PMC: 4461037. DOI: 10.1158/1078-0432.CCR-11-1667. View

12.

van der Schaft D, Hillen F, Pauwels P, Kirschmann D, Castermans K, Oude Egbrink M . Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res. 2005; 65(24):11520-8. DOI: 10.1158/0008-5472.CAN-05-2468. View

13.

Potente M, Gerhardt H, Carmeliet P . Basic and therapeutic aspects of angiogenesis. Cell. 2011; 146(6):873-87. DOI: 10.1016/j.cell.2011.08.039. View

14.

Filipazzi P, Huber V, Rivoltini L . Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother. 2011; 61(2):255-263. PMC: 11029611. DOI: 10.1007/s00262-011-1161-9. View

15.

Davis B, Rothenberg M . Eosinophils and cancer. Cancer Immunol Res. 2014; 2(1):1-8. DOI: 10.1158/2326-6066.CIR-13-0196. View

16.

Bergers G, Brekken R, McMahon G, Vu T, Itoh T, Tamaki K . Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000; 2(10):737-44. PMC: 2852586. DOI: 10.1038/35036374. View

17.

Cirri P, Chiarugi P . Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res. 2011; 1(4):482-97. PMC: 3186047. View

18.

Orimo A, Gupta P, Sgroi D, Arenzana-Seisdedos F, Delaunay T, Naeem R . Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005; 121(3):335-48. DOI: 10.1016/j.cell.2005.02.034. View

19.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

20.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View